U

Urteste SA
WSE:URT

Watchlist Manager
Urteste SA
WSE:URT
Watchlist
Price: 92 PLN 4.07% Market Closed
Market Cap: 129.7m PLN
Have any thoughts about
Urteste SA?
Write Note

Urteste SA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Urteste SA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
U
Urteste SA
WSE:URT
Current Portion of Long-Term Debt
zł315k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Current Portion of Long-Term Debt
zł1.7m
CAGR 3-Years
-54%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Current Portion of Long-Term Debt
zł43.3m
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
-9%
S
Synthaverse SA
WSE:SVE
Current Portion of Long-Term Debt
zł21.2m
CAGR 3-Years
53%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Urteste SA
Glance View

Market Cap
129.7m PLN
Industry
Biotechnology

Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.

URT Intrinsic Value
11.44 PLN
Overvaluation 88%
Intrinsic Value
Price
U

See Also

What is Urteste SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
315k PLN

Based on the financial report for Dec 31, 2023, Urteste SA's Current Portion of Long-Term Debt amounts to 315k PLN.

What is Urteste SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
154%

Over the last year, the Current Portion of Long-Term Debt growth was 154%.

Back to Top